LA 419

Drug Profile

LA 419

Alternative Names: LA-419

Latest Information Update: 26 Aug 2015

Price : $50

At a glance

  • Originator Lacer
  • Class Ischaemic heart disorder therapies; Small molecules; Sugar alcohols
  • Mechanism of Action Antioxidants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ischaemic heart disorders

Most Recent Events

  • 26 Aug 2015 Phase-II development is ongoing in Spain
  • 21 Sep 2010 LA 419 is still in phase II trials for Ischaemic heart disorders in Spain
  • 07 May 2007 Phase-II clinical trials in Ischaemic heart disorders in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top